Method for treating respiratory viral infections comprising administration of fatty acid compositions
Methods and compositions comprising free fatty acids for the treatment, including prevention, of viral infections, including the treatment of Acute Respiratory Distress Syndrome (ARDS). The compositions comprising free fatty acids, optionally linolenic acid, linoleic acid, and/or palmitic acid, may be used in methods for treating viral infections, optionally, coronavirus infections, for example, SARS-CoV, MERS-CoV, and/or SARS-CoV-2/COVID-19, and influenza virus infections, optionally, H1N1 and/or H5N1.
1. A method for treating a subject suffering from acute respiratory distress syndrome (ARDS) comprising administering a composition comprising an effective amount of a free fatty acid, a derivative thereof, or a combination thereof to a subject in need,
wherein the composition comprises a combination of oleic acid, linoleic acid, and
palmitic acid; and
wherein the subject is suffering from a viral infection.
2. The method of claim 1 , wherein the viral infection is coronavirus, influenza A virus, influenza B virus, enterovirus, respiratory syncytial virus (RSV), parainfluenza, adenovirus, or a combination thereof.
3. The method of claim 2 , wherein the coronavirus is SARS-CoV, MERS-CoV, SARS-CoV-2/COVID-19, or a combination thereof.
4. The method of claim 3 , wherein the coronavirus is SARS-CoV2/COVID-19.
5. The method of claim 1 , wherein the fatty acid derivative is a Coenzyme A (CoA) fatty acid derivative or a synthetic homologues thereof.
6. The method of claim 1 , wherein the fatty acid is a saturated fatty acid.
7. The method of claim 1 , wherein the fatty acid is an unsaturated fatty acid.
8. The method of claim 1 , wherein the composition is a pharmaceutical composition comprising an effective amount of a fatty acid and a carrier.
9. The method of claim 8 , wherein the carrier is an excipient, lubricant, antioxidant, emulsifier, stabilizer, solvent, diluent, buffer, vehicle, or a combination thereof.
10. The method of claim 1 , wherein the composition further comprises a phospholipid, water, isotonic solution, glycerin, salt, base, amino acid, sugar, antioxidant, or a mixture thereof.
11. The method of claim 1 , wherein the composition is formulated for administration to the oral cavity, larynx, nasal cavity, optionally sinus, lungs, vagina, rectum, or a combination thereof.
12. The method of claim 1 , wherein the composition is formulated an emulsion, gel, optionally vaginal gel, suppository, optionally vaginal suppository, foam, vaginal tablets, cream, optionally vaginal cream, vaginal ring, enema, optionally micro-enema, large-volume enema, for administration by a specialized catheter, aerosol, mist, or a combination thereof.
13. The method of claim 1 , wherein the composition is substantially free of arachidic acid, arachidonic acid, behenic acid, brassidic acid, butyric acid, capric acid, caproic acid, caproleic acid, caprylic acid, cerotic acid, dihomo-γ-linolenic acid (DGLA), linolenic acid, docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), eicosapentaenoic acid (EPA), elaidic acid, eurcic acid, gadoleic acid, lauric acid, lauroleic acid, lignoceric acid, linoelaidic acid, α-linoleic acid, γ-linoleic acid, mead acid, myristic acid, myristoleic acid, nervonic acid, palmitoleic acid, pinolenic acid (columbinic acid), sapienic acid, stearic acid, vaccenic acid, «-linoleic acid, or a combination thereof.
14. The method of claim 1 , wherein the composition is substantially free of triglycerides.
15. The method of claim 1 , wherein the composition comprising a fatty acid is an emulsion.
16. The method of claim 1 , wherein the administration comprises subcutaneous, intramuscular, intravenous, intraperitoneal, intrapleural, intravesicular, intrathecal, topical, nasal, inhalation, oral administration, or a combination of routes.
17. The method of claim 1 , wherein the composition further comprises an anti-viral drug.